Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
J Psychopharmacol ; 24(8): 1175-81, 2010 Aug.
Article in English | MEDLINE | ID: mdl-19204062

ABSTRACT

The neural basis of generalized anxiety disorder (GAD) is poorly characterized. The effect of chronic administration (12 weeks) of paroxetine, a selective serotonin reuptake inhibitor, on N-acetylaspartate (NAA), a marker of neuronal viability, was evaluated in adults with GAD using proton magnetic resonance spectroscopic imaging ((1)H MRSI) at 1.5 T. We hypothesized that, pretreatment abnormalities in hippocampal NAA/creatine (NAA/Cr) would normalize with symptomatic improvement. Nine GAD patients (mean age = 41.7 year; 4 females) received 12 weeks of open-label paroxetine treatment, flexibly dosed up to 60 mg/day. Clinical outcome was assessed with the Hamilton Anxiety Rating Scale (HAM-A). Multislice ( 1)H MRSI scans were performed at unmedicated baseline and following 6 and 12 weeks of treatment. Ten untreated healthy volunteers (HVs) (mean age = 37.1 year; 4 females) received scans at the same intervals. All patients achieved remission (HAM-A

Subject(s)
Anxiety Disorders/drug therapy , Aspartic Acid/analogs & derivatives , Hippocampus/drug effects , Neurons/metabolism , Paroxetine/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology , Adult , Anxiety Disorders/metabolism , Aspartic Acid/metabolism , Creatine/metabolism , Female , Hippocampus/metabolism , Humans , Male , Middle Aged , Neurons/drug effects , Paroxetine/administration & dosage , Paroxetine/adverse effects , Pilot Projects , Psychiatric Status Rating Scales , Selective Serotonin Reuptake Inhibitors/administration & dosage , Selective Serotonin Reuptake Inhibitors/adverse effects , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...